AVE(SH:688067) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-10-22 01:00Core Viewpoint - The company, Awei Technology Co., Ltd., is making a strategic investment of 10 million RMB in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake, which aligns with its long-term development goals and aims to enhance its competitive edge in the medical imaging sector [2][13][14]. Investment Overview - The total investment amount for this round is 30 million RMB, with Awei Technology contributing 10 million RMB to subscribe for 249.3766 thousand RMB of the new registered capital of Luying Technology [4][8]. - The investment does not require board or shareholder approval as it falls within the general manager's authority and has completed internal decision-making processes [5][14]. Target Company Information - Hunan Luying Technology Co., Ltd. specializes in the development of high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [6][13]. - The company was established less than a year ago and currently does not have any sales revenue or profit [6][16]. Market Context - The global medical imaging and radiation therapy equipment market is experiencing rapid and stable growth, with significant government support for the domestic nuclear medicine industry, particularly in promoting the localization of nuclear medicine imaging equipment [13][14]. - SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has a strong market outlook, making it a strategic area for investment [13][14]. Strategic Implications - This investment is expected to deepen synergies within the company's main business and enhance its overall competitiveness, aligning with its strategic development plans [13][14]. - The funding for this investment comes from the company's own resources and will not adversely affect its normal operations or financial status [14]. Future Considerations - The success of this investment will depend on Luying Technology's future operational performance and its ability to navigate various risks associated with market conditions, technology development, and regulatory approvals [16].